Autarkic drug discovery in Japanese pharmaceutical companies: Insights into national differences in industrial innovation

Research Policy

Volumn 32, Issue 10, 2003, Pages 1805-1827

  Kneller, Robert ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Alliances; Collaboration; Culture; Drug development; Japan; Licensing; Pharmaceuticals; Research management; Start ups

Indexed keywords

BIOMEDICAL ENGINEERING; BIOTECHNOLOGY; DRUG PRODUCTS; DRUG PRODUCTS PLANTS; PERSONNEL TRAINING; RESEARCH AND DEVELOPMENT MANAGEMENT; SOCIETIES AND INSTITUTIONS;

DRUG DEVELOPMENT; DRUG DISCOVERY;

INDUSTRIAL RESEARCH;

EID: 0345356389     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0048-7333(03)00062-3     Document Type: Article

References (43)

1. Aventis, 2001. Research and development: top 10 companies pipeline, available at http://www.pharma.aventis.com.au/research/pipeline/top10.htm .
2. Brody, J., 2001. Myths abound about eczema: new drugs said to bring relief. New York Times Service, International Herald Tribune, 21 June, p. 10.
3. Cockburn, I., Henderson, R., 1997. Public-private interaction and the productivity of pharmaceutical research. NBER Working Paper 6018.
4. Coleman, S., 1999. Japanese Science: From the Inside. Routledge, London.
5. Doi, T., 1971. The Anatomy of Dependence. Kodansha, Tokyo.
6. Ernst and Young, 2000a. Convergence: the biotechnology industry report. Millennium edition, available at http://www.ey.com.
7. Ernst and Young, 2000b. Evolution: seventh annual European life science report 2000, available at http://www.ey.com .
8. Florida R. The globalization of R&D: results of a survey of foreign-affiliated R&D laboratories in the USA. Research Policy. 26:1997;85-103.
9. Galambos L., Sturchio J. Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation. Business History Review. 72:1998;250-278.
10. Grandstrand O. Internationalization of corporate R&D: a study of Japanese and Swedish corporations. Research Policy. 28:1999;275-302.
11. Hess, A. (Vice President, Corporate Market Development, ISI/Thomson Scientific), 2001. Corporate Bioscience Publication in Japan: 1981-2000. Unpublished report on file with author.
12. Hicks D. University-industry research links in Japan. Policy Sciences. 26:1993;361-395.
13. HSBC, 2000a. Sector report. Global Pharmaceutical Review.
14. HSBC, 2000b. Japan Pharmaceuticals.
15. JBA (Japan Bioindustry Association), 2003. 333 Bioventures, press release (in Japanese).
16. JPMA (Japan Pharmaceutical Manufacturer's Association), 2002. Data Book 2002, p. 12.
17. Kimura, B., et al., 1993. The current state and problems of Japan's pharmaceutical market. In: Okimoto, D., Yoshikawa, A. (Eds.), Japan's Health System: Efficiency and Effectiveness in Universal Care. Faulkner &Gray's Healthcare Information Center, Washington, DC, pp. 171-189.
18. Kneller R. Intellectual property rights and university-industry technology transfer in Japan. Science and Public Policy. 26:1999;113-124. available under "reports" (RM 99-08) at http://www.nsftokyo.org.
19. Kneller R. University-industry cooperation in high technology. Japan Inc. 2:2000;26-31. available at http://www.Japaninc.net.
20. Kneller, R., 2003. University-industry cooperation and transfer of intellectual property rights in Japan compared with the US: another reason for Japan's economic malaise? University of Pennsylvania Journal of International Economic Law 24 (2), in press.
21. Kuemmerle W. Foreign direct investment in industrial research in the pharmaceutical and electronics industries - results from a survey of multinational firms. Research Policy. 28:1999;179-193.
22. Lam, A., 2003. Organisational learning in multinationals: R&D networks of Japanese and US MNEs in the UK. Journal of Management Studies 40, 673-703.
23. Leigh, B. (Assistant Director, Worldwide Academic Liaison, for SmithKline Beecham), 2000. In: Proceedings of the Presentation at the Annual Conference of Licensing Executive Society International, Amsterdam, 23 May.
24. Murray F. Innovation as co-evolution of scientific and technological networks: exploring tissue engineering. Research Policy. 31:2002;1389-1403.
25. Nakane, C., 1970. Japanese Society. Tate-shakai (Vertical Society) is more Revealing. University of California Press, Berkeley (Japanese title).
26. Nayak, K., Kneller, R., in press. University-industry cooperation in Japan on MRI development: foreign companies lead the way.
27. Odagiri, H., 1999. University-industry collaboration in Japan: facts and interpretations. In: Branscomb, L., Kodama, F., Florida, R. (Eds.), Industrializing Knowledge: University-Industry Linkages in Japan and the United States. MIT Press, Cambridge, MA, pp. 269-306.
28. Odagiri, H., 2001. Transaction costs and capabilities as determinants of the R&D boundaries of the firm: a case study of the ten largest pharmaceutical firms in Japan. Discussion Paper No. 19. National Institute of Science and Technology Policy (NISTEP) and the Ministry of Education, Culture, Sports, Science and Technology (MEXT).
29. Pearce R., Papanastassiou M. Overseas R&D and the strategic evolution of MNEs: evidence from laboratories in the UK. Research Policy. 28:1999;23-41.
30. Pechter, K., 2001. Measuring the university-industry linkage in Japan. Ph.D. dissertation on file with author.
31. Pharmaceutical Manufacturers Association of America (PhRMA), 2001. Survey: new medicines in development for cancer. PhRMA, Washington, DC, available at http://www.phrma.org under "for the press".
32. Pharmaceutical Manufacturers Association of America (PhRMA), 2001. Survey: new medicines in development for heart disease and stroke. PhRMA, Washington, DC, available at http://www.phrma.org under "for the press".
33. Pharmaceutical Manufacturers Association of America (PhRMA), 2002. Survey: new medicines in development for infectious diseases. PhRMA, Washington, DC, available at http://www.phrma.org under "for the press".
34. Protein Engineering in Japan, 1992. Report of a US protein engineering study team on its visit to Japan. US Government internal report.
35. Reger G. How R&D is coordinated in Japanese and European multinationals. R&D Management. 29:1999;71-88.
36. Salat P., Parikh V. Motilin receptor agonists as novel gastrointestinal prokinetic agents. Indian Journal of Pharmacology. 31:1999;333-339.
37. Tack J., Peters T. What comes after macrolides and other motilin stimulants? Gut. 49:2001;317-318.
38. Thomas, L., 2001. The Japanese Pharmaceutical Industry: The New Drug Lag and the Failure of Industrial Policy. Elgar, Cheltenham, UK.
39. Van Brunt, J., 2000. Pharma's new vision. Signals Magazine, available at http://www.signalsmag.com .
40. Van Brunt, J., 2002. Inflection point. Signals Magazine, available at http://www.signalsmag.com .
41. Westney, E., 1999. Changing perspectives on the organization of Japanese multinational companies. In: Beechler, S., Bird, A. (Eds.), Japanese Multinationals Abroad: Individual and Organizational Learning. Oxford University Press, New York.
42. Yamagishi T. Uncertainty, trust and commitment formation in the United States and Japan. American Journal of Sociology. 104:1998;165-194.
43. Zucker L., Darby M. Present at the biotechnology revolution. Research Policy. 26:1997;429-446.